The 23-year ERSPC trial reveals that sustained, protocolized PSA testing lowers prostate cancer deaths and improves the benefit-to-harm ratio, supporting a shift toward risk-based, patient-centered screening strategies.
European…
The 23-year ERSPC trial reveals that sustained, protocolized PSA testing lowers prostate cancer deaths and improves the benefit-to-harm ratio, supporting a shift toward risk-based, patient-centered screening strategies.
European…